Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RU-486 "approvable" decision occurs on Sept. 18 user fee deadline.

Executive Summary

RU-486 DECISION DEADLINE COINCIDES WITH CONGRESSIONAL DEBATE on President Clinton's veto of a ban on partial birth abortions. The confluence of FDA's publicly stated Sept. 18 deadline for a decision on the abortifacient and the Congressional attention to the veto gave political resonance to FDA's decision to grant "approvable status" to mifepristone. Following the advisory committee review of mifepristone in July, FDA Commissioner Kessler declared the agency would make a decision by the six-month user fee deadline of Sept. 18 ("The Pink Sheet" July 22, p. 3).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028906

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel